Table 3.
Cytogenetics at diagnosis.
| Studies without a Comparator | Studies with a Comparator | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shin 2017 [10] |
Jurczyszyn 2019 [13] |
Pál 2020 [14,15] |
Duek 2021 [15] |
Caulier 2021 [16] |
Pydi 2021 [22] |
Bao 2022 [17] h |
Ludwig 2008 [9] |
Jurczyszyn 2016 [19] |
Lu 2016 [18] |
Nakaya 2020 [21] |
|||||
| Age studied (years) |
≤40 | ≤30 | ≤40 | <50 | ≤40 | ≤40 | <50 | <50 | ≥50 | 21–40 | 41–60 | <50 | ≥50 | <40 years | All patients Median 74 |
| Hyperdiploid | NA | NA | 6/11 (55) | 1/22 (4.5) |
NA | NA | NA | NA | NA | NA | NA | 3/33 (9) | 8/120 (7) | NA | NA |
| Non-hyperdiploid | NA | 19/21 (90) | NA | NA | NA | NA | Hypodiploid 5/210 (2) |
NA | NA | NA | NA | 4/33 (12) | 24/120 (20) | NA | NA |
| t(11;14) | NA | 1/20 (5) | NA | 15/22 (68) a,b | 9/35 (26) | 2/7 (29) | 42/210 (20) | NA | NA | NA | NA | NA | NA | 1/5 (20) | 83/316 (26) p = 0.461 |
| t(14;16) | 0/11 (0) | NA | NA | 0/22 (0) | 1/39 (2.5) | 1/7 (14) | NA | NA | NA | NA | NA | NA | NA | 0/7 (0) | 27/532 (5) p = 0.063 |
| t(14;20) | 0/6 (0) | NA | NA | 0/22 (0) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| t(8;14) | NA | NA | NA | NA | NA | NA | 4/210 (2) | NA | NA | NA | NA | NA | NA | NA | NA |
| t(4;14) | 1/10 (10) | 0/20 (0) | 3/11 (27) | 0/22 (0) | 19/156 (12) e | 1/7 (14) | 15/210 (7) | NA | NA | 26/81 (32) j | 31/181 (17) j p = 0.007 |
NA | NA | 2/8 (25) | 168/802 (21) p = 0.659 |
| del (17p)/17 delp53 |
1/9 (11) | 2/21 (10) | 2/11 (18) | 1/22 (4.5) | 17/141 (12) e | 1/7 (14) | 15/210 (7) | NA | NA | 17/91 (19) i | 61/351 (17) p 0.771 i |
3/9 (33) | 86/606 (14) p = 0.008 |
||
| + or amp 1q21/1q gain | 4/15 (27) | 2/17 (12) | NA | NA | 17/56 (30) f | NA | 48/210 (23) | NA | NA | NA | NA | 49/87 (56) i | 139/313 (44) p = 0.064 i |
NA | NA |
| del (1p32) | NA | NA | NA | 1/22 (4.5) c | 8/46 (17) g | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| del (13q)/ del 13 |
4/17 (24) | 8/26 (31) | NA | 9/22 (40) d | NA | 3/7 (43) | 72/210 (34) | 32/53 (60) i | 150/320 (47) p = 0.069 i |
NA | NA | 13/37 (35) i | 58/141 (41) p = 0.507 i |
4/8 (50) | 211/435 (49) p = 1.000 |
| 17/109 (16) ii | 45/345 (13) p = 0.499 ii |
3/33 (9) ii | 9/120 (8) p = 0.767 ii |
||||||||||||
| del (9) | 1/16 (6) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
NA: not available. a sole aberration in 32%; b 3 also had IgH rearrangement, 6 also had del 13q, 1 also had delp53; c 1 also IgH rearranged; d 1 also had delp53, 6 also t(11;14), 3 also IgH rearranged, 1 also del 16q; e 2 patients had t(4;14) and del (17p); f Associated with high-risk cytogenetics in 5 patients; g Associated with high-risk cytogenetics in 2 patients and associated with +1q in 5 patients; h 7% had ≥2 high-risk chromosomal abnormalities; i by FISH; ii by conventional cytogenetics; j del (17p) and t(4;14) merged. Numbers in parentheses represent percentages.